Cambiamento dell’isotipo di componenti monoclonali note: due casi clinici

  • Maria Paola Simula
  • Annalisa Fabris
  • Gianluca Festini
  • Maurizio Ruscio
Lettera
First Online:
Received:
Accepted:
  • 97 Downloads

Isotype change of monoclonal components: two clinical cases

This is a preview of subscription content, log in to check access.

Notes

Conflitti di interesse

Nessuno.

Studi condotti su esseri umani e animal

Per questo tipo di studio non è richiesto l’inserimento di alcuna dichiarazione relativa agli studi effettuati su esseri umani e animali.

Consenso informato

Il consenso informato è stato ottenuto da tutti i pazienti inclusi nello studio.

Bibliografia

  1. 1.
    Ruggeri M, Bottan F, Chiarugi P et al. (2001) Linee guida per la diagnostica ed il monitoraggio delle gammapatie monoclonali. Riv Med Lab-JLM 2(S1):68–71 Google Scholar
  2. 2.
    Caldini A, Graziani MS, Basile U et al. (2014) Il contributo della diagnostica proteica nella gestione delle gammapatie monoclonali. Biochimica Clinica 38:47–53 Google Scholar
  3. 3.
    Dimopoulos M, Kyle R, Fermand JP et al. (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:4701–4705 CrossRefPubMedGoogle Scholar
  4. 4.
    Kyle RA, Durie BG, Rajkumar SV et al. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121–1127 CrossRefPubMedGoogle Scholar
  5. 5.
    Berenson JR, Anderson KC, Audell RA et al. (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28–38 PubMedGoogle Scholar
  6. 6.
    Bird J, Behrens J, Westin J et al. (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 147:22–42 CrossRefPubMedGoogle Scholar
  7. 7.
    Durie BG, Harousseau JL, Miguel JS et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473 CrossRefPubMedGoogle Scholar
  8. 8.
    Wadhera RK, Kyle RA, Larson DR et al. (2011) Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 118:2985–2987 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Kyle RA, Therneau TM, Rajkumar SV et al. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569 CrossRefPubMedGoogle Scholar
  10. 10.
    Rajkumar SV, Kyle RA, Therneau TM et al. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812–817 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Turesson I, Kovalchik SA, Pfeiffer RM et al. (2014) Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123:338–345 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Società Italiana di Patologia Clinica e Medicina di Laboratorio 2016

Authors and Affiliations

  1. 1.DAI Medicina di LaboratorioAzienda Sanitaria Universitaria IntegrataTriesteItalia
  2. 2.Ematologia ClinicaAzienda Sanitaria Universitaria IntegrataTriesteItalia

Personalised recommendations